VCAM1 and Miyoshi myopathy: Moreover, the inhibition of MM cell adhesion to VCAM-1 by both antibodies suggests that targeting CD38 can disrupt crucial interactions for MM cell retention in the bone marrow, potentially reducing drug resistance and improving treatment outcomes.